Quince Therapeutics Presents Preclinical Data at MHSRS 2022 Demonstrating Preclinical Efficacy of Bone-targeting Platform for Traumatic Bone Injury
September 16 2022 - 8:00AM
Business Wire
Quince Therapeutics, Inc. (Nasdaq: QNCX), a biopharmaceutical
company advancing innovative precision therapeutics targeting
debilitating and rare diseases, today detailed highlights from the
company’s participation at the Military Health System Research
Symposium (MHSRS 2022), which took place September 12 to September
15, 2022, in Kissimmee, Florida. At MHSRS 2022, Quince presented a
poster showcasing the broad applicability of the company’s highly
differentiated bone-targeting platform and potential to accelerate
healing directly at the site of bone injury in traumatic
indications.
Stewart Low, Ph.D., Quince’s head of discovery, said, “As we
continue to leverage and expand our core bone-targeting platform
across promising indications, we believe there is an opportunity to
introduce a novel method for accelerating the healing of traumatic
bone injury. By concentrating at the site of injury, preclinical
studies show that our lead NOV004 molecule can serve as a targeted
potent bone growth stimulating drug that can dramatically shorten
broken bone healing times and improve overall patient
outcomes.”
MHSRS 2002 Poster Highlights
The following are highlights from the company’s poster
presentation of preclinical data of NOV004 at MHSRS 2022:
Poster: Engineered Bone Fracture Targeted Parathyroid Hormone
Agonist as an Effective Pharmaceutical for Accelerated Bone Repair
in Mouse and Canine Models
- Each year in the U.S., there are more than 18 million fractures
leading to more than $50 billion in direct medical costs. NOV004 is
a fracture-targeted bone anabolic agent that concentrates
selectively on the bone fracture surface and induces accelerated
bone formation only at the damaged site.
- Quince believes that the systemic administration of NOV004
could provide a potential opportunity to treat stress fractures,
multisite trauma, as well as operative and nonoperative fractures.
There are currently no FDA approved systemic therapies for fracture
repair.
- In preclinical studies, Quince observed a decrease in fracture
healing time by 50% in NOV004 treated groups. Additionally, bone
deposition and max load doubled and the force required to
refracture the bones increased more than two-fold in mouse
models.
To view the poster presented at MHSRS 2022, please visit the
Science section of Quince’s corporate website.
About Quince Therapeutics
Quince Therapeutics is focused on advancing innovative precision
therapeutics targeting debilitating and rare diseases. The company
discovered a broad bone-targeting drug platform designed to
precisely deliver small molecules, peptides, or large molecules
directly to the site of bone fracture and disease to promote more
rapid healing with fewer off-target safety concerns compared to
non-targeted therapeutics. Quince’s discovery pipeline is
positioned for rapid expansion across multiple skeletal therapeutic
indications to address underserved therapeutic areas with major,
unmet medical needs, including osteogenesis imperfecta, fractures,
spinal fusion, and other severe bone diseases. The company’s lead
compound NOV004 is an anabolic peptide engineered to precisely
target and concentrate at the bone fracture site, which preclinical
studies demonstrate result in rapid increases in bone density,
strength, and healing directly at the site of bone fracture. NOV004
is expected to enter Phase 1 clinical studies in 2023 and advance
to a lead indication in osteogenesis imperfecta. For more
information, visit www.quincetx.com and follow Quince Therapeutics
on LinkedIn and @Quince_Tx on Twitter.
Forward-looking Statements
Statements in this news release contain “forward-looking
statements” that are subject to substantial risks and
uncertainties. Forward-looking statements contained in this news
release may be identified by the use of words such as “anticipate,”
“expect,” “will,” “can,” “may,” “should,” “estimate,” “project,”
“potential,” “encouraged,” “positioned,” or other similar words.
Examples of forward-looking statements include, among others, the
clinical development and strategic development path for NOV004; the
timing and success of the company’s clinical trials and related
data, including plans and the ability to initiate, conduct and/or
complete the Phase 1 clinical studies for NOV004; the potential
therapeutic benefits, safety, and efficacy of the company’s
bone-targeting platform, product candidate and discovery pipeline.
Forward-looking statements are based on Quince Therapeutics’
current expectations and are subject to inherent uncertainties,
risks, and assumptions that are difficult to predict and could
cause actual results to differ materially from what the company
expects. Further, certain forward-looking statements are based on
assumptions as to future events that may not prove to be accurate.
Factors that could cause actual results to differ include, but are
not limited to, the risks and uncertainties described in the
section titled “Risk Factors” in the company’s Annual Report on
Form 10-K filed with the Securities and Exchange Commission (SEC)
on March 1, 2022, its Quarterly Report on Form 10-Q filed with the
SEC on August 9, 2022, and other reports as filed with the SEC.
Forward-looking statements contained in this news release are made
as of this date, and Quince Therapeutics undertakes no duty to
update such information except as required under applicable
law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220916005037/en/
Quince Therapeutics Contact: Stacy Roughan Quince
Therapeutics, Inc. Vice President, Corporate Communications &
Investor Relations ir@quincetx.com
Quince Therapeutics (NASDAQ:QNCX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Quince Therapeutics (NASDAQ:QNCX)
Historical Stock Chart
From Sep 2023 to Sep 2024